Project Grant R41DA056270
Award Date
9/1/22
Completion Date
8/31/23
Dollars Obligated
$640K
Federal Agency
National Institute on Drug Abuse
Awardee
Olfa Thera, Inc. (C8PGYYTCSAR4)
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This $399,536 Project Grant was awarded by the National Institute on Drug Abuse (NIDA), a part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research to design, synthesize, and test non-opioid drug candidates that can help combat the national opioid crisis, with a focus on reversing the effects of synthetic opioids like fentanyl. The key goals are to: 1) Develop and characterize chemical lead compounds and control...
The University of Chicago was awarded a $712,167 Project Grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant will fund research to investigate the mechanisms by which the opioid drug fentanyl activates the carotid body, a sensory organ that regulates breathing, in order to develop therapeutic strategies for mitigating opioid-induced respiratory depression (OIRD) - a major health concern. The project...
This Project Grant award, valued at $671,732, was issued by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The purpose of the award is to evaluate the use of peripherally-acting mu opioid receptor (MOR) antagonists to prevent and reverse fentanyl-induced respiratory depression, a major cause of opioid overdose deaths, while minimizing withdrawal and aversion side effects. Key objectives include assessing peripheral MOR...
This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the broader Drug Use and Addiction Research Programs (CFDA 93.279), is supporting the development of a novel overdose reversal agent by Serodopa Therapeutics, Inc. The $1,539,426 award aims to complete formulation development and preclinical testing to prepare an Investigational New Drug (IND) application for the company's intranasal naloxone derivative. This novel agent is designed to more effectively reverse...
The National Institute on Drug Abuse (NIDA) awarded a $581,914 project grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Texas A&M University System Health Science Center. The 5-year grant, effective August 1, 2024, seeks to uncover the biological basis for why sleep apnea patients are more sensitive to opioid-induced respiratory depression (OIRD), which is a leading cause of opioid overdose deaths. The research will investigate how oxytocin neurotransmission from...
This Project Grant award from the National Institutes of Health (NIH) Office of the Director, funded under the Trans-NIH Research Support program (CFDA 93.310), aims to improve understanding of serotonin mechanisms involved in fentanyl-induced respiratory depression. The $1,378,272 award to the Regents of the University of Michigan, with a project period running from June 2024 to April 2027, will support research to: Determine the effect of fentanyl on the activity of serotonin neurons in the...
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, awarded a $399,589 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Resilient Lifescience, Inc. on September 15, 2024. The grant's objective is to develop a wearable medical device capable of detecting opioid overdose. The project is scheduled for completion by August 31, 2025. The Drug Use and Addiction Research Programs support a wide range of research activities to advance...
This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $1,557,845 to Regents of the University of Michigan to investigate the brainstem mechanisms of opioid-induced respiratory depression. The proposed research aims to determine how non-opioid-sensitive neurons in the dorsolateral pons contribute to breathing failure during opioid overdose, with the goal of generating a more complete...
The National Institute on Drug Abuse (NIDA) awarded a $800,000 Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to Biosensics LLC to develop ODALERT, a wearable device for the automatic detection of opioid-induced respiratory arrest. The project aims to create an innovative solution to address the escalating opioid crisis in the United States by detecting respiratory depression and alerting users and first responders to potential opioid overdoses. In Phase...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $398,137 to Boston Interactome LLC to develop high-precision epigenetic therapeutics for opioid use disorder (OUD). The project aims to identify functional modulators of the neuronal G9A complex, which regulates DFosB expression during chronic opioid exposure, and biophysically characterize their drug-protein interactions. The efficacy...